Omeros provides update on zaltenibart trial
Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...
The American Journal of Managed Care8d
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
Healio11d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
manilatimes13d
Sezzle Announces Six-for-One Stock Split and $50 Million Stock Repurchase Program
Minneapolis, MN, March 10, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ: SEZL,) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company's Board of ...
The Bakersfield Californian13d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ( ...
Business Insider13d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...
contemporarypediatrics28d
DB-OTO demonstrates improved hearing in 10 of 11 children with profound genetic hearing loss
New, positive data for Regeneron Pharmaceuticals' DB-OTO gene therapy among children with profound genetic hearing loss were presented at the Association for Research in Otolaryngology’s (ARO) 48 th ...